The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial

Bobo, William V.; Woodward, Neil D.; Sim, Min Young; Jayathilake, Karuna; Meltzer, Herbert Y.

doi:10.1016/j.schres.2011.05.015

Cited by 34 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the pragmatic difficulties of ensuring antipsychotic adherence in SZ patients, it is viewed by some as problematic to prescribe a drug (AMPH) that might trigger activate psychosis in the absence of antipsychotics. Other psychostimulants, such as modafinil, are being investigated for their potential pro-cognitive effects (Bobo et al 2011; Kane et al 2010; Scoriels et al 2012), and might also prove to enhance the therapeutic impact of cognitive interventions.…”

Section: Discussionmentioning

confidence: 99%

Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults

et al. 2013

View full text Add to dashboard Cite

Background Cognitive deficits contribute strongly to functional disability in schizophrenia. The cost of identifying and testing candidate procognitive agents is substantial. Conceivably, candidate drugs might be first identified by positive effects on cognitive domains in sensitive subgroups of healthy subjects. Here, we examined whether the MATRICS Consensus Cognitive Battery (MCCB) detected procognitive drug effects in subgroups of healthy individuals. Methods The effects of 20 mg amphetamine (AMPH) on MCCB performance were tested in a double-blind, placebo-controlled crossover study of 60 healthy adults. AMPH effects were compared in subgroups of subjects characterized by low vs. high placebo MCCB scores, and by extreme values on personality subscales associated with schizophrenia-relevant biomarkers. Results AMPH produced autonomic and subjective effects, but did not significantly change MCCB composite scores or individual domain scores across the inclusive sample of 60 subjects. AMPH-induced MCCB changes were significantly (inversely) related to placebo MCCB performance: among individuals with lower placebo scores, AMPH enhanced performance, while among individuals with higher placebo scores, it impaired performance. A potential impact of regression to the mean was assessed, and could not be ruled out. Both placebo MCCB performance and AMPH effects on MCCB scores were significantly related to personality domains associated with schizophrenia-linked genetic- and/or neurophysiological substrates. Conclusions Among healthy adults, AMPH effects on MCCB performance were detected only among specific subgroups, and in specific cognitive domains. Strategies that utilize drug-induced changes in MCCB performance in healthy subjects to screen for candidate procognitive drugs should consider the use of “enriched” subgroups with specific neurocognitive or personality characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This agent has also given positive results not only in healthy subjects but also in cognitively high-functioning subjects as chess players (Franke et al, 2017). However, its potential beneficial effects still remain unclear in schizophrenia, with discrepant results (Bobo et al, 2011.) Taking into account all these data, some authors have hypothesized that specific subgroups of patients may benefit in cognitive performance from adjunctive modafinil.…”

Section: Future Clinical Directionsmentioning

confidence: 99%

Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies

Solé

Jiménez

Torrent³

et al. 2017

International Journal of Neuropsychopharmacology

215

138

View full text Add to dashboard Cite

Over the last decade, there has been a growing appreciation of the importance of identifying and treating cognitive impairment associated with bipolar disorder, since it persists in remission periods. Evidence indicates that neurocognitive dysfunction may significantly influence patients’ psychosocial outcomes. An ever-increasing body of research seeks to achieve a better understanding of potential moderators contributing to cognitive impairment in bipolar disorder in order to develop prevention strategies and effective treatments. This review provides an overview of the available data from studies examining treatments for cognitive dysfunction in bipolar disorder as well as potential novel treatments, from both pharmacological and psychological perspectives. All these data encourage the development of further studies to find effective strategies to prevent and treat cognitive impairment associated with bipolar disorder. These efforts may ultimately lead to an improvement of psychosocial functioning in these patients.

show abstract

“…Additionally, compared to other depressive symptoms, anhedonia is usually the last to resolve (Rubin, 2012). Although not impossible (Bobo, Woodward, Sim, Jayathilake, & Meltzer, 2011), anhedonia in schizophrenia is also difficult to treat (Couture, Blanchard, & Bennett, 2011; Grant, Huh, Perivoliotis, Stolar, & Beck, 2012). Hence, further understanding of anhedonia may help improve depression remission rates.…”

Section: Concept Analysis Resultsmentioning

confidence: 99%

Anhedonia: A Concept Analysis

Sommers

2013

Archives of Psychiatric Nursing

View full text Add to dashboard Cite

Anhedonia presents itself in a myriad of disease processes. To further develop our understanding of anhedonia and effective ways to manage it, the concept requires clear boundaries. This paper critically examined the current scientific literature and conducted a concept analysis of anhedonia to provide a more accurate and lucid understanding the concept. As part of the concept analysis, this paper also provides model, borderline, related, and contrary examples of anhedonia.

show abstract

The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial

Cited by 34 publications

References 53 publications

Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults

Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults

Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies

Anhedonia: A Concept Analysis

Contact Info

Product

Resources

About